Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions

Jacobus Lubsen, Z. Vokó, Philip A. Poole-Wilson, Bridget Anne Kirwan, Sophie de Brouwer

Research output: Article

7 Citations (Scopus)

Abstract

Background and Objective: Whether blood pressure (BP) reduction is a necessary prerequisite for cardiovascular risk reduction or an epiphenomenon has not been definitively established. We used an innovative analytic method to address this question. Methods: For 7,287 participants in a stable angina trial comparing long-acting nifedipine to placebo, we estimated the BP response after 2 weeks of treatment corrected for regression-to-the mean, and then related the latter and assigned treatment to subsequent cardiovascular outcomes. Results: Subsequent stroke and heart failure was strongly related to 2-week corrected systolic BP response, but coronary angiography and bypass surgery was not. Adjustment for the 2-week corrected systolic BP response changed nifedipine effect estimates (relative to placebo) for subsequent stroke from 28% (P = 0.04) to 21% (P = 0.13) risk reduction, and for heart failure from 30% (P = 0.02) to 21% (P = 0.11) risk reduction; but did not alter the effect estimates for coronary angiography (27% reduction, P <0.001), and coronary bypass surgery (22% reduction, P = 0.002). Conclusion: The stroke and heart failure risk reduction by nifedipine GITS in patients with stable angina can be attributed partly to its BP lowering effect, whereas effects on coronary procedures are likely to be related almost entirely to its antianginal effects.

Original languageEnglish
Pages (from-to)720-726
Number of pages7
JournalJournal of Clinical Epidemiology
Volume60
Issue number7
DOIs
Publication statusPublished - júl. 2007

Fingerprint

Stable Angina
Nifedipine
Heart Failure
Stroke
Blood Pressure
Risk Reduction Behavior
Coronary Angiography
Placebos
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions. / Lubsen, Jacobus; Vokó, Z.; Poole-Wilson, Philip A.; Kirwan, Bridget Anne; de Brouwer, Sophie.

In: Journal of Clinical Epidemiology, Vol. 60, No. 7, 07.2007, p. 720-726.

Research output: Article

Lubsen, Jacobus ; Vokó, Z. ; Poole-Wilson, Philip A. ; Kirwan, Bridget Anne ; de Brouwer, Sophie. / Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions. In: Journal of Clinical Epidemiology. 2007 ; Vol. 60, No. 7. pp. 720-726.
@article{09f3b88a334e49b5be7245ca6b739c22,
title = "Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions",
abstract = "Background and Objective: Whether blood pressure (BP) reduction is a necessary prerequisite for cardiovascular risk reduction or an epiphenomenon has not been definitively established. We used an innovative analytic method to address this question. Methods: For 7,287 participants in a stable angina trial comparing long-acting nifedipine to placebo, we estimated the BP response after 2 weeks of treatment corrected for regression-to-the mean, and then related the latter and assigned treatment to subsequent cardiovascular outcomes. Results: Subsequent stroke and heart failure was strongly related to 2-week corrected systolic BP response, but coronary angiography and bypass surgery was not. Adjustment for the 2-week corrected systolic BP response changed nifedipine effect estimates (relative to placebo) for subsequent stroke from 28{\%} (P = 0.04) to 21{\%} (P = 0.13) risk reduction, and for heart failure from 30{\%} (P = 0.02) to 21{\%} (P = 0.11) risk reduction; but did not alter the effect estimates for coronary angiography (27{\%} reduction, P <0.001), and coronary bypass surgery (22{\%} reduction, P = 0.002). Conclusion: The stroke and heart failure risk reduction by nifedipine GITS in patients with stable angina can be attributed partly to its BP lowering effect, whereas effects on coronary procedures are likely to be related almost entirely to its antianginal effects.",
keywords = "Angina pectoris, Blood pressure change, Coronary artery disease, Covariance analysis, Nifedipine, Regression-to-the-mean",
author = "Jacobus Lubsen and Z. Vok{\'o} and Poole-Wilson, {Philip A.} and Kirwan, {Bridget Anne} and {de Brouwer}, Sophie",
year = "2007",
month = "7",
doi = "10.1016/j.jclinepi.2006.10.015",
language = "English",
volume = "60",
pages = "720--726",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions

AU - Lubsen, Jacobus

AU - Vokó, Z.

AU - Poole-Wilson, Philip A.

AU - Kirwan, Bridget Anne

AU - de Brouwer, Sophie

PY - 2007/7

Y1 - 2007/7

N2 - Background and Objective: Whether blood pressure (BP) reduction is a necessary prerequisite for cardiovascular risk reduction or an epiphenomenon has not been definitively established. We used an innovative analytic method to address this question. Methods: For 7,287 participants in a stable angina trial comparing long-acting nifedipine to placebo, we estimated the BP response after 2 weeks of treatment corrected for regression-to-the mean, and then related the latter and assigned treatment to subsequent cardiovascular outcomes. Results: Subsequent stroke and heart failure was strongly related to 2-week corrected systolic BP response, but coronary angiography and bypass surgery was not. Adjustment for the 2-week corrected systolic BP response changed nifedipine effect estimates (relative to placebo) for subsequent stroke from 28% (P = 0.04) to 21% (P = 0.13) risk reduction, and for heart failure from 30% (P = 0.02) to 21% (P = 0.11) risk reduction; but did not alter the effect estimates for coronary angiography (27% reduction, P <0.001), and coronary bypass surgery (22% reduction, P = 0.002). Conclusion: The stroke and heart failure risk reduction by nifedipine GITS in patients with stable angina can be attributed partly to its BP lowering effect, whereas effects on coronary procedures are likely to be related almost entirely to its antianginal effects.

AB - Background and Objective: Whether blood pressure (BP) reduction is a necessary prerequisite for cardiovascular risk reduction or an epiphenomenon has not been definitively established. We used an innovative analytic method to address this question. Methods: For 7,287 participants in a stable angina trial comparing long-acting nifedipine to placebo, we estimated the BP response after 2 weeks of treatment corrected for regression-to-the mean, and then related the latter and assigned treatment to subsequent cardiovascular outcomes. Results: Subsequent stroke and heart failure was strongly related to 2-week corrected systolic BP response, but coronary angiography and bypass surgery was not. Adjustment for the 2-week corrected systolic BP response changed nifedipine effect estimates (relative to placebo) for subsequent stroke from 28% (P = 0.04) to 21% (P = 0.13) risk reduction, and for heart failure from 30% (P = 0.02) to 21% (P = 0.11) risk reduction; but did not alter the effect estimates for coronary angiography (27% reduction, P <0.001), and coronary bypass surgery (22% reduction, P = 0.002). Conclusion: The stroke and heart failure risk reduction by nifedipine GITS in patients with stable angina can be attributed partly to its BP lowering effect, whereas effects on coronary procedures are likely to be related almost entirely to its antianginal effects.

KW - Angina pectoris

KW - Blood pressure change

KW - Coronary artery disease

KW - Covariance analysis

KW - Nifedipine

KW - Regression-to-the-mean

UR - http://www.scopus.com/inward/record.url?scp=34250022182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250022182&partnerID=8YFLogxK

U2 - 10.1016/j.jclinepi.2006.10.015

DO - 10.1016/j.jclinepi.2006.10.015

M3 - Article

VL - 60

SP - 720

EP - 726

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 7

ER -